Skip to main content

Table 3 Treatment duration, and length of hospital stay

From: Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden

 

Treatment

Resource use (days)

Source

Treatment duration

 First-line treatment for IA

Isavuconazole

47.1 (IV: 8.1)

Mean treatment duration from SECURE [11, 39]a

Voriconazole

47.1 (IV: 8.1)

 First-line treatment for mucormycosis

Isavuconazole

Voriconazole no pathogen information available

Voriconazole non-responders prior to switching

149.0 (IV: 15.5)

47.1 (IV: 8.1)

11.0 (IV: 8.1)

Mean treatment duration from VITAL [12, 36]

Patients treated as IA patients, assumption follows SECURE [11, 39]

Median time between first clinical signs and mucormycosis diagnosis, Xhaard et al. [17]

 Second-line treatment for IA

L-AmB

14.5 (IV: 14.5)

Median treatment duration from Leenders et al. [19]

Oral step-down with voriconazole or posaconazole

32.6 (IV: 0)

Total duration of second-line treatment b minus duration of treatment with liposomal amphotericin-B

 Second-line treatment for mucormycosis

L-AmB

27.2 (IV: 27.2)

Median treatment duration from VITAL Fungiscope case-control [12, 36]

Posaconazole

121.8 (IV: 0)

Total duration of second-line treatmentc minus duration of treatment with liposomal amphotericin-B

Length of hospital stay

 IA

Isavuconazole

Voriconazole

L-AmB

19.7

19.7

19.7

Mean duration from SECURE [11, 39]a

 Mucormycosis

Isavuconazole

19.3

Mean duration from VITAL [12, 36]

Voriconazole no pathogen information available

19.3

Assumption same as for isavuconazole

Voriconazole non-responders prior to switching

11.0

Duration of treatment before mucormycosis diagnosis from Xhaard et al. [17]

L-AmB + posaconazole

27.2

Assumed: Duration the same as the mean days of IV treatment in Fungiscope case-control (VITAL [12, 36])

  1. aAs there was no statistical difference between treatment groups in SECURE study, the same value was taken for isavuconazole, voriconazole and L-AmB
  2. bThe total duration of second-line treatment for IA was assumed to be the equivalent to that for isavuconazole that for first-line treatment for IA (47.1 days)
  3. cThe total duration of second-line treatment for mucormycosis was assumed to be the equivalent to that for first-line treatment for mucormycosis with isavuconazole (149.0 days). IA, invasive aspergillosis; IV, intravenous; L-AmB, liposomal amphotericin B